CNW -- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its corporate partner, Cook Medical, reported data on two-year follow up that showed that 82 percent of patients who were treated with Cook Medical’s Zilver(R) PTX(TM) drug-eluting peripheral stent (DES) were free from reintervention at two-year follow up. The Zilver PTX Registry study, involving 792 patients from across the world, is assessing the safety and efficacy of the Zilver PTX in treating PAD. The most recent results were reported at the 31st International Symposium: Charing Cross Controversies Challenges Consensus.
